Gamm Lab Discoveries Culminate in FDA Approval of a Clinical Trial for the Treatment of Inherited Photoreceptor Diseases
BlueRock Therapeutics LP, a clinical stage cell therapy company and subsidiary of Bayer AG, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-based cell therapy for the treatment of primary photoreceptor diseases. Discoveries over the past …